Study of Intravenous TAD® 600 Mg/4 ML Solution for Injection to Evaluate Efficacy and Safety in Preventing Myocardial Injury in Patients with Pneumonia.

Inclusion Criteria * Patients with an age of ≥ 18 and ≤ 80 years * Diagnosis of CAP or HAP requiring hospitalization * Patients with one of the following : \- At least one cardiovascular comorbidity: * Chronic atrial fibrillation * History of ischemic heart disease (≥ 3 months) * Heart failure * Cardiac Valvular Disease * Previous (≥ 6 months) episode of myocarditis or pericarditis. \- Very high risk of developing cardiovascular diseases according to the SCORE2 and SCORE2-OP risk models for moderate risk European regions (score ≥ 7.5% for patients \< 50 years old, score ≥ 10% for patients 50-69 years old, and score ≥ 15% for patients ≥ 70 years old). * Provision of written informed consent as approved by the Ethics Committee (EC). Exclusion Criteria Medical Conditions: * Active malignancy * Severe heart failure (NYHA class III and IV) * End-stage renal failure (eGFR \< 30 mL/min) * Severe liver disease * History of hypersensitivity to glutathione or any excipients * Use of drugs containing sacubitril * Use of drugs with antioxidant activity in the last 3 months * Use of narcotics * Use of invasive mechanical ventilation * Recent (\< 3 months) ACS (STEMI, NSTEMI, UA), myocardial revascularization, myocarditis, acute pericarditis episodes. General Conditions: * Pregnant or breastfeeding women * Women of child-bearing potential not using at least one effective contraceptive method for the entire trial * Participation in other investigational drug or device clinical trials within 30 days prior to study screening * Patients legally or mentally incapacitated unable to give informed consent for the participation in this trial * Patients unable or unwilling to comply with the appointments after hospitalization or with all the requirements of the Protocol.